Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript)Seeking Alpha • 11/28/23
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?The Motley Fool • 11/10/23
Biogen lowers full-year earnings guidance, 3Q revenue beats expectationsProactive Investors • 11/08/23
Compared to Estimates, Biogen Inc. (BIIB) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/08/23
Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatmentMarket Watch • 11/08/23
Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses MountInvestors Business Daily • 11/08/23
Countdown to Biogen Inc. (BIIB) Q3 Earnings: A Look at Estimates Beyond Revenue and EPSZacks Investment Research • 11/06/23
Biogen Inc. (BIIB) Rises But Trails Market: What Investors Should KnowZacks Investment Research • 10/30/23
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's TreatmentInvestors Business Daily • 10/26/23
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in studyCNBC • 10/25/23
Biogen and Eisai release new Alzheimer's drug data that may support wider uptakeMarket Watch • 10/25/23
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On AlzheGlobeNewsWire • 10/25/23